Proof-of-Concept
Sonnet BioTherapeutics has established preclinical proof-of-concept with our albumin binding ScFv whereby we demonstrate up to 10x increases in serum half-life and improved tumor penetration. We have also demonstrated that immune modulating cytokines delivered via Sonnet’s albumin-binding scaffold achieve improved antitumor activity.
Highlights
- Demonstrated a 10-fold increase in serum half-life using three different targets of interest (either recombinant cytokines or immune modulating ScFvs) when linked to our albumin binding antibody fragment
- Demonstrated that recombinant human cytokines linked to Sonnet’s albumin binding single chain antibody fragment:
- Retain biologic activity in mice
- Preferentially modulate immune response within tumors
- Significantly enhance antitumor activity (tumor size and median survival in the anti-PD1 refractory B16F10 mouse model)
- Demonstrated dose-dependent efficacy with a single dose of Sonnet’s cytokine-FHAB in preclinical mouse tumor models
- Demonstrated superior efficacy with a single dose of Sonnet’s cytokine-FHAB compared to the parent recombinant human cytokine
- Demonstrated superior activity compared to a PD-1 antibody in a PD-1 refractory mouse tumor model
- Demonstrated ability to link two different cytokines to the same albumin binding antibody fragment (FHAB) and retain full biologic activity for each cytokine in in vitro assays
- Demonstrated that Sonnet’s dual cytokine-FHAB retained biologic activity in a mouse tumor model